Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H.
about
Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GNTherapeutic regulation of complement in patients with renal disease - where is the promise?Production of biologically active complement factor H in therapeutically useful quantitiesGain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome.Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains.Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H.Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals.The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndromeGenetics and complement in atypical HUS.A novel deletion in the RCA gene cluster causes atypical hemolytic uremic syndrome.Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein.Complement activation in thrombotic microangiopathiesEculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene.Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?Dynamics of complement activation in aHUS and how to monitor eculizumab therapyAnalysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation.Complement mutations in diacylglycerol kinase-ε-associated atypical hemolytic uremic syndrome.The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease.A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan.Complete remission of thrombotic microangiopathy after treatment with eculizumab in a patient with non-Shiga toxin-associated bacterial enteritis: A case report.Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders.Comparative proteomic analysis of serum from patients with systemic sclerosis and sclerodermatous GVHD. Evidence of defective function of factor HCurrent evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activityComplement System Part I - Molecular Mechanisms of Activation and Regulation.Current concepts in C3 glomerulopathy.The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesis-generating studyDense deposit disease.A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor HC3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation.Translational mini-review series on complement factor H: structural and functional correlations for factor H.The C-terminus of complement factor H is essential for host cell protection.The complement factor H-related proteins.C3b and factor H: key components of the complement system.The Serine Protease Pic From Enteroaggregative Escherichia coli Mediates Immune Evasion by the Direct Cleavage of Complement Proteins.The Murine Factor H-Related Protein FHR-B Promotes Complement ActivationAn extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy.Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications.Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome.
P2860
Q26741542-2FA875EC-DD5D-4F5D-838E-3F09DF83B253Q26851705-8CFBE18B-7A1B-42FB-9E49-AEA11D46FE54Q28300280-30CACE71-D93E-45FD-844A-67775C4E56C1Q33373674-C67D44B6-3C45-4A20-AB29-43CDD132A34FQ33375335-EF86D09E-4983-4328-B6C0-66FD804A23E5Q33377799-CFE75AE5-764E-49C3-B59B-10F81A0574E3Q33378236-6FA9F676-BAE5-41C1-AF46-B825D83BB584Q33378469-60582A43-47C7-4AFD-A65A-EDB168515A86Q33389945-31089319-D6E2-4129-85FC-C01040280B41Q33392449-9F227FD2-D61E-48A6-AF94-2B2FA8DD5EE5Q33399052-7C98EB14-7EA9-4FDC-A0FC-3741731A380FQ33400705-33C4B3DF-0E5F-4149-B036-6BEC42B9D3C8Q33404158-1E8F45C5-8AC1-4E71-9285-48F8476F9208Q33410033-D150007C-3F89-479F-B9FA-AE0854DAF782Q33414109-052A574D-82C6-4222-985F-9C836C041603Q33416519-34060B27-38A6-4776-83E0-1E322EB76987Q33417165-4B591DBD-000E-4C7D-9D38-92E349B712DBQ33417173-611A72E4-3937-4F88-919D-56CEC604399EQ33420213-0FB8AB29-E7D9-40A4-A361-1EEBA9E90A75Q33422650-26E930F7-26CB-4E9B-AB84-93499A50D466Q33433788-21200746-32C6-4BC3-888E-6D115F21AB0CQ33437488-1FD79663-189F-4159-A666-15D52002700DQ33668640-C46AF862-5D7C-49BD-BADE-FA838CB2D243Q33783126-A481365D-1175-484F-82D4-0F1266E270C2Q33972574-2D3475C9-03F1-4D52-BFC2-D28E53513419Q34481071-15516CCA-ABD5-48EF-B168-D2738729D9BCQ34574482-5B2B51E7-0045-4816-B2FE-54D6DAE52F4DQ35057817-E03B2035-4AD0-4F06-95CF-8543A2EF825CQ35124165-8C24506C-59F0-49D7-887D-87054970DB12Q35809292-CC498CD0-764E-4CDC-B4CA-EFD977133B06Q36891110-21BF249E-E6E7-4E61-AF10-292699A0E559Q37032788-8C7412E6-CE74-411E-84FE-604C75D8075AQ37238656-B77757BC-EBBB-4182-8AFE-272162300AEAQ38991052-A8A237F0-B2CE-40E8-B5F8-F9919E6ADBFBQ40292881-D4E85EE5-5A6D-476F-87EB-A036D0B39797Q41547882-B7734E20-BD48-4C0B-84B2-2CDA9CEAD909Q42039533-21780CB2-6702-48DB-8EBF-46D19A7BFD46Q42625961-0D23EFC5-60AB-4D09-A0B7-512C7C1E8C12Q46433084-B961EE72-DE69-48E1-A4E7-DDD877EF5245Q47674559-3D416B8A-3888-4F29-9F38-2435B24BB27D
P2860
Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Functional analysis in serum f ...... ed with mutations in factor H.
@ast
Functional analysis in serum f ...... ed with mutations in factor H.
@en
type
label
Functional analysis in serum f ...... ed with mutations in factor H.
@ast
Functional analysis in serum f ...... ed with mutations in factor H.
@en
prefLabel
Functional analysis in serum f ...... ed with mutations in factor H.
@ast
Functional analysis in serum f ...... ed with mutations in factor H.
@en
P1433
P1476
Functional analysis in serum f ...... ted with mutations in factor H
@en
P2093
González-Rubio C
Sánchez-Corral P
P356
10.1016/J.MOLIMM.2004.01.003
P577
2004-05-01T00:00:00Z